Recent Finacing
Recent Raise
ScarX Therapeutics develops SCX-001, a topical nefopam formulation that modulates beta-catenin to reduce hypertrophic post-surgical scarring and improve wound healing, progressing into Phase I clinical testing.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors